Mode
Text Size
Log in / Sign up
N/A Completed N=8,314

E-Five Registry: A World-Wide Registry With The Endeavor Zotarolimus Eluting Coronary Stent

Source: ClinicalTrials.gov NCT00623441 ↗
Enrolled (actual)
8,314
Serious AEs
1.7%
Results posted
Dec 2011
Primary outcomePrimary: MACE (Major Adverse Cardiac Events) — 7.5 Percentage of participants

Summary

The safety and efficacy of the Endeavor(TM) ABT-578 Eluting Coronary Stent System has been assessed in a series of studies. The stent is coated with a proprietary drug compound that is designed to reduce restenosis. This prospective multi-center study has been initiated: * To document the acute and mid-term safety and overall clinical performance of the stent system in a "real world" patient population requiring stent implantation. * To assess the event rate in patient subgroups with specific clinical indications and/or vessel or lesion characteristics.

Outcome Measures

OutcomeResultp-value
PRIMARY
MACE (Major Adverse Cardiac Events)
7.5 —

Eligibility Criteria

Inclusion Criteria

  • Patient is >18 years of age (or minimum age as required by local regulation)
  • The patient has consented to participate by signing the "Patient Informed Consent Form" and/or has authorized the collection and release of his medical information by signing the "Patient Data Release Consent Form".
  • The patient is suitable for implantation of one or more Endeavor(TM) ABT-578 Eluting Coronary Stent System in one or more native artery target lesions.
  • Lesion length and vessel diameter of the target lesion(s) are according to the "Indications for Use" as mentioned in the "Instructions for Use" that comes with every Endeavor(TM) ABT-578 Eluting Coronary Stent System.
  • The patient is willing and able to cooperate with registry procedures and required follow up visits.

Exclusion Criteria

  • Women with known pregnancy or who are lactating.
  • Patients with hypersensitivity or allergies to aspirin, heparin, clopidogrel, ticlopidine, drugs such as ABT-578, rapamycin, tacrolimus, sirolimus or similar drugs, or any other analogue or derivative, cobalt, chromium, nickel, molybdenum or contrast media.
  • Patients in whom anti-platelet and/pr anticoagulation therapy is contraindicated.
  • Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon.
  • Current medical condition with a life expectancy of less than 12 months.
  • The subject is participating in another device or drug study. Subject must have completed the follow-up phase of any previous study at least 30 days prior to enrollment in this trial. The subject may only be enrolled in this E-five registry once.
  • Patients with medical conditions that preclude the follow-up as defined in the protocol or that otherwise limits participation in this registry.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00623441). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search